According to an iHub poster, the stock of InoLife Technologies Inc (PINK:INOL) ‘will deliver and in fact surprise and go over a dollar in to three dollars’. Seen from an investors’ perspective, this statement sounds fairly promising. However, is it realistic?
Last Friday, INOL stock went up 30%, closing the session at its Jun. 17 level of $0.0017 per share. The volume, on the other hand, also enjoyed a significant spike with more than 148 million shares changing hands, thus marking the company’s second highest score in June. The latter also turned out to be four times higher than the average daily trading volume.
Newswise, INOL has been fairly prolific for the last several weeks. Yet, Friday’s surge in price has nothing to do with news as long as there have been no official updates since Jun. 15. Neither have any promotional programs occurred, which is strange considering that INOL has one of the most heavily promoted stocks for quite a while now.
According to its corporate website, Iolife Technologies’s mission goes down to identifying and developing a string of healthcare products and service solutions aimed at giving patients accurate data regarding their generic makeup, predisposition to diseases, etc. In collaboration with InoHealth Products, Inc., INOL pretends to be offering ‘the best DNA analysis products on the market. ‘
As far as INOL’s financial policy is concerned, it appears to be fairly transparent, hence the company’s OTCQB classification. However, investors are still waiting for a full-blown 10-Q covering Q1 of 2011. Unless INOL submits one in due course, it will most probably bid farewell to the OTCQB marketplace.
